Цефтазидим-MIP

Основна информация

  • Търговско наименование:
  • Цефтазидим-MIP 1g прах за инжекционен/инф.разтвор
  • Използвай за:
  • Хората
  • Вид на лекарството:
  • алопатични наркотици

Документи

Локализация

  • Предлага се в:
  • Цефтазидим-MIP 1g прах за инжекционен/инф.разтвор
    България
  • Език:
  • български

Терапевтична информация

  • Каталог на резюме:
  • Ceftazidim-MIP, 1g powder for solution for injection/infusion x 1; x 5; x 10 vials

Друга информация

Състояние

  • Източник:
  • Изпълнителна агенция по лекарствата - Bulgarian Drug Agency - Bulgaria
  • Номер на разрешението:
  • 20150170
  • Дата Оторизация:
  • 26-05-2015
  • Последна актуализация:
  • 01-06-2018

Листовка за пациента: състав, показания, Нежелани лекарствени реакции, дозиране, взаимодействия, бременност, кърмене

30-10-2018

Pest categorisation of Aleurocanthus spp.

Pest categorisation of Aleurocanthus spp.

Published on: Mon, 29 Oct 2018 00:00:00 +0100 The Panel on Plant Health performed a pest categorisation of Aleurocanthus spp., a well‐defined insect genus of the whitefly family Aleyrodidae (Arthropoda: Hemiptera). Difficulties within the taxonomy of the genus give doubt about the ability to accurately identify some members to species level. Nevertheless, the genus is thought to currently include about ninety species mainly reported from tropical and subtropical areas. The genus is listed in Council Dir...

Europe - EFSA - European Food Safety Authority Publications

8-10-2018

Clomifene / clomiphene

Clomifene / clomiphene

Update 3 - continuing medicine shortage

Therapeutic Goods Administration - Australia

28-9-2018

FDA approves first treatment for advanced form of the second most common skin cancer

FDA approves first treatment for advanced form of the second most common skin cancer

FDA approves Libtayo (cemiplimab-rwlc) for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for curative surgery or curative radiation. This is the first FDA approval of a drug specifically for advanced CSCC.

FDA - U.S. Food and Drug Administration

9-9-2011

Danish Pharmacovigilance Update, 18 August 2011

Danish Pharmacovigilance Update, 18 August 2011

Among the topics covered in this issue are Vimpat® 15mg/ml syrup (lacosamide) for treatment of epilepsy, which is recalled due to a quality defect and Nplate® (romiplostim), which could increase the risk of disease progression in patients with myelodysplastic syndrome (MDS).

Danish Medicines Agency

15-5-2018

Pramipexole Accord (Accord Healthcare Limited)

Pramipexole Accord (Accord Healthcare Limited)

Pramipexole Accord (Active substance: pramipexole) - Centralised - Yearly update - Commission Decision (2018)2995 of Tue, 15 May 2018

Europe -DG Health and Food Safety

3-5-2018

Pramipexole Teva (Teva B.V.)

Pramipexole Teva (Teva B.V.)

Pramipexole Teva (Active substance: pramipexole) - Centralised - Yearly update - Commission Decision (2018)2775 of Thu, 03 May 2018

Europe -DG Health and Food Safety

2-2-2018

MiPet Easecto (Zoetis Belgium S.A.)

MiPet Easecto (Zoetis Belgium S.A.)

MiPet Easecto (Active substance: sarolaner) - New authorisation - Commission Decision (2018)656 of Fri, 02 Feb 2018 European Medicines Agency (EMA) procedure number: EMEA/V/C/4732

Europe -DG Health and Food Safety